Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22013956 | 1.00 | DGAT1 (0.36) | DGAT1NPC1MAPT | |
| SCHEMBL19023210 | 0.86 | SPR (0.36) | DGAT1NPC1MAPT | |
| SCHEMBL19250755 | 0.85 | NPC1 (0.32) | DGAT1NPC1MAPT | |
| SCHEMBL30908091 | 0.81 | NPC1 (0.39) | DGAT1NPC1MAPT | |
| SCHEMBL30908064 | 0.80 | MAPT (0.37) | DGAT1NPC1MAPT | |
| SCHEMBL1592603 | 0.80 | MAPT (0.37) | DGAT1NPC1MAPT | |
| SCHEMBL22553893 | 0.80 | DGAT1 (0.35) | DGAT1MAPT | |
| SCHEMBL22013944 | 0.79 | NPC1 (0.37) | DGAT1NPC1MAPT | |
| SCHEMBL30908117 | 0.79 | NPC1 (0.37) | DGAT1NPC1MAPT | |
| SCHEMBL30908118 | 0.79 | NPC1 (0.37) | DGAT1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391687-B2 | Five-and-six-membered heterocyclic compound and use thereof as protein receptor kinase inhibitor | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2025-08-19 | — | — | US | disclosed |
| EP-3919490-B1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | SHANGHAI ENNOVABIO PHARMACEUTICALS CO LTD (CN) | 2025-04-02 | — | — | EP | disclosed |
| CN-113166142-B | Five-membered and six-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors | 上海轶诺药业有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20220144827-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391687-B2 | Five-and-six-membered heterocyclic compound and use thereof as protein receptor kinase inhibitor | GRK6, GRK3, ERBB2 | DGAT1 3470/4885NPC1 2977/4885MAPT 2101/4885 |
| US-20220144827-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | GRK6, GRK3, ERBB2 | DGAT1 3470/4885NPC1 2977/4885MAPT 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.